AR068837A1 - Formas solidas de acido (s)amino-3-(4-(2- amino 6-((r)2,2,2-trifluoro-1-(3-metoxi)piridin-4-il)propanoico y sus sales, metodos de tratamiento y metodo de preeparacion del compuesto y sus formas de dosificacion - Google Patents

Formas solidas de acido (s)amino-3-(4-(2- amino 6-((r)2,2,2-trifluoro-1-(3-metoxi)piridin-4-il)propanoico y sus sales, metodos de tratamiento y metodo de preeparacion del compuesto y sus formas de dosificacion

Info

Publication number
AR068837A1
AR068837A1 ARP080104405A ARP080104405A AR068837A1 AR 068837 A1 AR068837 A1 AR 068837A1 AR P080104405 A ARP080104405 A AR P080104405A AR P080104405 A ARP080104405 A AR P080104405A AR 068837 A1 AR068837 A1 AR 068837A1
Authority
AR
Argentina
Prior art keywords
amino
trifluoro
salts
propanoic
preeparation
Prior art date
Application number
ARP080104405A
Other languages
English (en)
Inventor
Wenxue Wu
Shinya Limira
Hui-Yin Li
Qiuling Song
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR068837(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of AR068837A1 publication Critical patent/AR068837A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen formas solidas de ácido (S)-2-amino-3-(4(2-amino-6-((R -2,2,2,trifluoro-1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico y sus sales, el compuesto cristalino en forma de propanoato-tosilato anhidro, hidrato, monohidrato, utiles para tratar el síndrome carcinoide y trastornos gastrointestinales e intestino irritable. Reivindicacion 4: El compuesto cristalino de acuerdo con la reivindicacion 3, caracterizado porque tiene un punto de fusion de aproximadamente 241 °C. Reivindicacion 5: El compuesto cristalino de acuerdo con la reivindicacion 3, caracterizado porque tiene un patron de difraccion de polvos por rayos X que comprende un pico en uno o varios de aproximadamente 3,5, 7,0, 8,6, 10,9, 13,5, 14,0, 15,1, 17,3, y/o 20,5 grados 2 thita. Reivindicacion 6: El compuesto de acuerdo con la reivindicacion 3, caracterizado porque tiene un patron de difraccion de polvos por rayos X sustancialmente igual al mostrado en la Figura 1.
ARP080104405A 2007-10-08 2008-10-08 Formas solidas de acido (s)amino-3-(4-(2- amino 6-((r)2,2,2-trifluoro-1-(3-metoxi)piridin-4-il)propanoico y sus sales, metodos de tratamiento y metodo de preeparacion del compuesto y sus formas de dosificacion AR068837A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97830307P 2007-10-08 2007-10-08

Publications (1)

Publication Number Publication Date
AR068837A1 true AR068837A1 (es) 2009-12-09

Family

ID=40344344

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104405A AR068837A1 (es) 2007-10-08 2008-10-08 Formas solidas de acido (s)amino-3-(4-(2- amino 6-((r)2,2,2-trifluoro-1-(3-metoxi)piridin-4-il)propanoico y sus sales, metodos de tratamiento y metodo de preeparacion del compuesto y sus formas de dosificacion

Country Status (20)

Country Link
US (1) US20090099206A1 (es)
EP (1) EP2231618A1 (es)
JP (1) JP2010540665A (es)
KR (1) KR20100066548A (es)
CN (1) CN101932563A (es)
AR (1) AR068837A1 (es)
AU (1) AU2008310979A1 (es)
BR (1) BRPI0818350A2 (es)
CA (1) CA2701904A1 (es)
CL (1) CL2008002980A1 (es)
CO (1) CO6270323A2 (es)
EA (1) EA201070455A1 (es)
EC (1) ECSP10010162A (es)
IL (1) IL204582A0 (es)
MX (1) MX2010003803A (es)
PE (1) PE20091213A1 (es)
TW (1) TW200932729A (es)
UY (1) UY31381A1 (es)
WO (1) WO2009048864A1 (es)
ZA (1) ZA201001870B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855291B2 (en) * 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
PT1984344E (pt) * 2005-12-29 2012-12-21 Lexicon Pharmaceuticals Inc Derivados de aminoácidos multicíclicos e métodos para a sua utilização
AU2008268409B2 (en) * 2007-06-26 2013-12-05 Lexicon Pharmaceuticals, Inc. Compositions comprising tryptophan hydroxylase inhibitors
TWI439457B (zh) 2007-09-28 2014-06-01 Lexicon Pharmaceuticals Inc （ｓ）－２－胺基－３－（４－（２－胺基－６－（（ｒ）－１－（４－氯－２－（３－甲基－１ｈ－吡唑－１－基）苯基）－２，２，２－三氟乙氧）－嘧啶－４－基）苯基）丙酸乙酯之固體形式與其使用方法
MX2010010799A (es) 2008-03-31 2011-03-25 Univ Columbia Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
WO2011063181A1 (en) * 2009-11-23 2011-05-26 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
US20130303763A1 (en) * 2012-03-30 2013-11-14 Michael D. Gershon Methods and compositions for the treatment of necrotizing enterocolitis
CN113227093A (zh) * 2018-11-14 2021-08-06 阿尔塔万特科学公司 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法
TW202210462A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 （ｓ）－２－胺基－３－（４－（２，３－二甲基吡啶－４－基）苯基丙酸甲酯及其鹽的製備方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7382793B1 (en) * 2002-01-17 2008-06-03 Juniper Networks, Inc. Systems and methods for determining the bandwidth used by a queue
US7855291B2 (en) * 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7897763B2 (en) * 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
PT1984344E (pt) * 2005-12-29 2012-12-21 Lexicon Pharmaceuticals Inc Derivados de aminoácidos multicíclicos e métodos para a sua utilização
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
AU2008268409B2 (en) * 2007-06-26 2013-12-05 Lexicon Pharmaceuticals, Inc. Compositions comprising tryptophan hydroxylase inhibitors
US20090005381A1 (en) * 2007-06-26 2009-01-01 Philip Manton Brown Methods of treating serotonin-mediated diseases and disorders
US7875622B2 (en) * 2007-07-11 2011-01-25 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
RU2010107066A (ru) * 2007-07-26 2011-09-10 Лексикон Фармасьютикалз, Инк. (Us) Способы воздействия на прохождение содержимого через желудочно-кишечный тракт и опорожнение желудка и используемые для этого соединения

Also Published As

Publication number Publication date
ECSP10010162A (es) 2010-06-29
KR20100066548A (ko) 2010-06-17
EP2231618A1 (en) 2010-09-29
EA201070455A1 (ru) 2010-08-30
ZA201001870B (en) 2011-06-29
CA2701904A1 (en) 2009-04-16
WO2009048864A1 (en) 2009-04-16
CN101932563A (zh) 2010-12-29
JP2010540665A (ja) 2010-12-24
CL2008002980A1 (es) 2009-03-20
MX2010003803A (es) 2010-04-21
BRPI0818350A2 (pt) 2017-10-10
TW200932729A (en) 2009-08-01
AU2008310979A1 (en) 2009-04-16
PE20091213A1 (es) 2009-08-26
US20090099206A1 (en) 2009-04-16
IL204582A0 (en) 2010-11-30
CO6270323A2 (es) 2011-04-20
UY31381A1 (es) 2009-04-30

Similar Documents

Publication Publication Date Title
AR068837A1 (es) Formas solidas de acido (s)amino-3-(4-(2- amino 6-((r)2,2,2-trifluoro-1-(3-metoxi)piridin-4-il)propanoico y sus sales, metodos de tratamiento y metodo de preeparacion del compuesto y sus formas de dosificacion
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
PE20131343A1 (es) Derivados de acido benzoico
PE20061098A1 (es) COMPUESTOS IMIDAZO[1,2-a] PIRIDINILO COMO INHIBIDORES DE VEGF-R2
PE20160874A1 (es) Compuestos quimicos
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
CL2008002315A1 (es) Compuestos derivados de acido piridin, pirimidin y quinolin aminonbenzoico; composicion y combinacion farmaceuticas; y uso para el tratamiento de una enfermedad susceptible de aliviarse mediante la inhibicion de deshidroorotato deshidrogenasa tales como artritis reumatoide, espondilitis anquilosante, esclerosis multiple, psoriasis, entre otras.
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
CO5670355A2 (es) Forma cristalina de sal de calcio de acido bis [(e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il](3r,5s)-3,5-dihidroxihept-6-enoico
CL2018000241A1 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il) propanoico sustituido.
AR080490A1 (es) FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA
BRPI0506610A (pt) montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
CY1124329T1 (el) N-(6-((2r,3s)-3,4-δiyδpoξyboytan-2-yλoξy)-2-(4-φθοροβενζυλοθειο)πυριμιδιν-4-υλ)-3-μεθυλαζετιδιν-1-σουλφοναμιδιο ως ρυθμιστης του υποδοχεα χημειοκινων
AR100818A1 (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
JP2016503010A5 (es)
WO2014153203A3 (en) Alkyl-amine harmine derivatives for promoting bone growth
PE20091087A1 (es) COMPUESTOS DERIVADOS DE 6-FENIL-1H-IMIDAZO[4,5-c]PIRIDINA-4-CARBONITRILO COMO INHIBIDORES DE CATEPSINA S Y/O CATEPSINA K
MX2020013311A (es) Composicion farmaceutica para administracion topica.
AR083755A1 (es) Formas solidas del acido (s)-2-amino-3-(4-(-2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pirimidin-4-il)fenil)propanoico
CL2020001346A1 (es) Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción.
PE20181895A1 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer
CO2021011836A2 (es) Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas
CO2018013416A2 (es) Sales farmacéuticas de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(l-metil-ih-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida y formas cristalinas de las mismas

Legal Events

Date Code Title Description
FB Suspension of granting procedure